What if #AI could design a drug that helps solve one of the biggest challenges in immunotherapy? At Aulos, we believe our lead asset, AU-007, could be the answer in safely harnessing the power of IL-2 to fight solid tumor cancers effectively.?? ? Learn how Aulos' approach works: https://bit.ly/4cao1MO? ? #Biopharma #Innovation #Oncology?
Aulos Bioscience
生物技术研究
Larkspur，California 1,939 位关注者
We’re revolutionizing #cancercare through #IL2 therapeutics designed to direct the #immunesystem to destroy cancers.
关于我们
Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems toward killing tumor cells. Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors. The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.
- 网站
-
https://aulosbio.com/
Aulos Bioscience的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Larkspur，California
- 类型
- 私人持股
- 领域
- immuno oncology 、oncology、monoclonal antibodies和cancer research
地点
-
主要
获取路线
700 Larkspur Landing Circle
Suite 108
US，California，Larkspur，94939
Aulos Bioscience员工
动态
-
Our novel therapeutic antibody was designed based on our belief that a biologic agent that looks like a natural antibody may be the key to unlocking the power of IL-2.?? ? See how our approach is different: https://bit.ly/3EuM3XZ ? #IL2 #Oncology Bioprocess Online??
-
Our lead asset, AU-007, is a human monoclonal antibody that we believe could safely and effectively unlock the anti-cancer power of interleukin-2 to fundamentally change cancer treatment. See how we’ve designed a drug candidate that could solve one of the biggest challenges in immunotherapy. Learn more:?https://bit.ly/4b5W1v7 #Innovation #Oncology #IL2?
-
Based on a growing body of evidence, our lead asset continues to demonstrate a well-tolerated safety profile and durable anti-tumor activity. Learn why our approach in redirecting IL-2 is showing promise: https://bit.ly/3EuM3XZ ? ? #Oncology #IL2 #Cancer??
-
-
At Aulos, we’re working to bring markedly improved treatment options to patients diagnosed with solid tumor cancers. Read about our mission and the values that guide us:? https://bit.ly/40FqrR0 #Mission #Values #Oncology #Biopharma
-
-
Good luck to all those presenting and networking at #JPM2025. We hope you enjoy your time in our hometown. If you’re attending the J.P. Morgan Healthcare Conference, we thought you might enjoy some history about the The Westin St. Francis San Francisco on Union Square. #JPM25 #JPMHC25 #biotech?
-
We were thrilled at the progress made in 2024 and we are excited for what the #NewYear will bring. Thank you to everyone who met us in person, participated in our trial or encouraged us online. Have a happy holiday season! #HappyHolidays #BioTech #HappyNewYear?
-
Following the science is a key discipline for success. Listen to our CEO, Aron Knickerbocker, and his advice for the next generation in #biotech, including how this principle has guided him throughout his career:? https://bit.ly/3YIbVpB #Oncology #BusinessofBiotech Bioprocess Online
-
This Thanksgiving, we are #thankful to everyone who helped make this an incredible year. A special thank you to the patients, families and investigators who are at the heart of our daily efforts. #Thanksgiving #patients #biopharma?
-
-
The first patient has been dosed in our #clinicaltrial collaboration with Merck KGaA, Darmstadt, Germany. The combination therapy is being evaluated in a Phase 2 cohort for treatment of non-small cell lung cancer.?? ? “We are excited to move forward with evaluating this combination therapy in a clinical setting after seeing encouraging synergy with AU-007 in preclinical studies. We thank Merck KGaA, Darmstadt, Germany, the patients and the clinical trial investigators who have chosen to participate in this clinical trial,” said CEO Aron Knickerbocker.?? ? Learn more here: https://bit.ly/3Z8IddJ ? #clinicaltrials #biopharma?
-